# A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

> **NCT05836896** · PHASE1 · RECRUITING · sponsor: **Technische Universität Dresden** · enrollment: 16 (estimated)

## Conditions studied

- Neoplasms
- Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
- Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Multiple Myeloma, Refractory
- Multiple Myeloma in Relapse

## Interventions

- **GENETIC:** MDC-CAR-BCMA001 (BCMA directed CAR T-cells)

## Key facts

- **NCT ID:** NCT05836896
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-15
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05836896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05836896, "A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05836896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*